Paramount Warner Bros deal advances after securing debt financing commitments for its proposed $81 billion acquisition of Warner Bros Discovery. The funding includes global lenders and Gulf-based investors, while the transaction awaits regulatory approvals across major markets.
Neurocrine enters metabolic disease space with $2.9B Soleno acquisition.
Nvidia’s SchedMD acquisition raises concerns about fairness and control in AI software infrastructure.
Gilead Sciences (GILD 0.72%) has entered into a definitive agreement to acquire Ouro Medicines in what is essentially a $2.18 billion deal. This strategic deal introduces the promising autoimmune therapy gamgertamig into Gilead’s inflammation world. The deal consists of an initial cash payment of $1.675 billion, plus milestones. And through this deal with Galapagos, they are looking to speed up these next-gen T cell engager drugs. This is a strong endorsement of Gilead’s commitment to medical innovation and further strengthens its position in the dynamic field of specialised biotechnology.
Copyright@ 2026 Inspirepreneurmagazine. All Rights Reserved.
